ArticleFrontiers in medicine2021
Advanced-Glycation End-Products Induce Podocyte Injury and Contribute to Proteinuria.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial.Diabetes, obesity & metabolism · 2026Trial
- Renal glycogen handling in diabetes: A narrative review of diabetic kidney disease pathogenesis.Journal of diabetes investigation · 2026Review
- Urinary Extracellular Vesicle-Derived miRNAs Reveal a Coordinated Stress-Response Network Linked to Advanced Glycation End-Products in Children and Adolescents.Antioxidants (Basel, Switzerland) · 2026Article
- ZhiXiaoSanZheng formula ameliorates podocyte injury in diabetic kidney disease by inhibiting ferroptosis: integrated network pharmacology and experimental validation.Chinese medicine · 2026Article
- Review
- Association between triglyceride-to-high-density lipoprotein cholesterol ratio and albuminuria in patients with type 2 diabetes: a cross-sectional study.Frontiers in nutrition · 2026Article
- Gene regulatory networks involved in activation of Notch signaling by AGEs in the pathogenesis of diabetic kidney disease.PloS one · 2026Article
- Serum Levels of NBiomedicines · 2025Article
- J-shaped association between metabolic score for visceral fat and albuminuria risk: a population-based study.Frontiers in endocrinology · 2025Article
- Serum advanced glycation end products as a putative biomarker in Type2 DKD patients' prognosis.Frontiers in physiology · 2025Article
- Cinnamaldehyde ameliorates diabetes-induced biochemical impairments and AGEs macromolecules in a pre-clinical model of diabetic nephropathy.BMC pharmacology & toxicology · 2024Article
- Value of radiomics-based two-dimensional ultrasound for diagnosing early diabetic nephropathy.Scientific reports · 2023Article
- Nε-Carboxymethyl-Lysine Modification of Extracellular Matrix Proteins Augments Fibroblast Activation.International journal of molecular sciences · 2023Article
- [Validation and comparison of diabetic retinopathy-based diagnostic models for diabetic nephropathy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Association between Urinary AGEs and Circulating miRNAs in Children and Adolescents with Overweight and Obesity from the Italian I.Family Cohort: A Pilot Study.Journal of clinical medicine · 2023Article
- Article
- Resveratrol Alleviates Advanced Glycation End-Products-Related Renal Dysfunction in D-Galactose-Induced Aging Mice.Metabolites · 2023Article
- Advanced Glycation End-Products and Their Effects on Gut Health.Nutrients · 2023Review
- Article
- Advances in the Preparation of Nanofiber Dressings by Electrospinning for Promoting Diabetic Wound Healing.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of diabetes reaches epidemic proportions. Diabetes is the leading cause of end-stage kidney disease (ESKD) since 30-40% of diabetic patients develop diabetic nephropathy. Albuminuria and glomerular filtration rate used to assess kidney function are considered surrogate outcomes of chronic kidney disease. The search for a biomarker that predicts progression to diabetic kidney disease is intense. We analyzed the association of serum advanced glycation end-products (AGEs) index (AGI) with impaired kidney function in poorly controlled type II diabetic patients. We observed an association between AGI and impaired kidney function in microalbuminuria patients with hyperglycemia. A significant association between AGEs, particularly carboxymethyl lysine (CML), and impaired kidney function were observed. Administration of AGEs to mice showed heavy proteinuria and glomerular abnormalities. Reduced podocyte number in mice administered with AGEs could be attributed to the epithelial-mesenchymal transition of podocytes. Our study suggests CML could be independently related to the podocyte injury and the risk of DN progression to ESKD in patients with microalbuminuria. AGEs in general or CML could be considered a prognostic marker to assess diabetic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.